Transcriptomic Biomarkers Indicate Early Sepsis

Transcriptomic biomarkers have been identified that indicate the presence of sepsis earlier and more reliably than currently available diagnostic tests.

Reliable biomarkers for the early observation of the inflammation status of sepsis are urgently needed. The molecular diagnostic test Siqnature provides the earliest possible information about the potential development of a systemic infection. The test can also be used to monitor the progression of sepsis and indicate patients at risk for the development of severe sepsis

SIRS-Lab (Jena, Germany) introduced Siqnature to the medical and lab personnel at the sixth International Shock Congress in Cologne (Germany), which took place from June 28-July 2, 2008. Clinical multicenter trials will mark the projected scientific launch of the routine test in late 2008.

In order to translate the biomarker information into clinically meaningful data, SIRS-Lab developed a new biostatistic program. The test result gives definite information about the existence and severity of a systemic infection.

Sirs-lab CEO Dr. Stefan Russwurm said, "After years of research and the successful implementation of the Vyoo pathogen kit, Siqnature is the cornerstone to fulfill Sirs-Lab's holistic diagnostic approach. Under the supervision of an internationally renowned scientific advisory board, prospective multicenter trials are now initiated to prove the clinical utility of the test. After the trial phase, Siqnature will be broadly available for clinical routine.”

The first clinical validation study of the diagnostic test was performed at the Jena University Hospital (Germany) with six hundred patients taking part.


Related Links:
SIRS-Lab
Jena University Hospital